Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus
Status:
Unknown status
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
Investigators will be determining whether a once weekly injectable medication Bydureon versus
placebo is able to reduce the development of atherosclerosis.
Investigators are testing the overall hypothesis that 18 months of Bydureon treatment will
improve cardiovascular risk factors, endothelial function and retard carotid atherosclerosis
plaque progression in type 2 diabetes mellitus (T2DM). Investigators anticipate these studies
will provide novel information about the temporal relationship between Bydureon induced
changes in risk factors, endothelial function and atherosclerosis progression.